MARKET

IMVT

IMVT

Immunovant Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

43.03
+0.08
+0.19%
Opening 13:15 10/30 EDT
OPEN
43.20
PREV CLOSE
42.95
HIGH
43.99
LOW
42.10
VOLUME
84.90K
TURNOVER
--
52 WEEK HIGH
43.99
52 WEEK LOW
8.34
MARKET CAP
3.75B
P/E (TTM)
-42.1739
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
UBS Initiates Coverage On Immunovant with Buy Rating, Announces Price Target of $61
UBS analyst Colin Bristow initiates coverage on Immunovant (NASDAQ:IMVT) with a Buy rating and announces Price Target of $61.
Benzinga · 2d ago
Billtrust to go public via South Mountain Merger
Billtrust enters into an agreement with South Mountain Merger (SMMCU) to go public with an implied estimated enterprise value of ~$1.3B, representing an 8.0x and 10.5x multiple to 2021 expected GAAP total revenue
Seekingalpha · 10/19 10:48
Blockbuster year for SPACs, an easier way to go public than a traditional IPOs
FY2020 till date has seen 127 SPAC IPOs, which collectively raised over $48.5B in proceeds, much more than the past ten years combined.Going public via a SPACs is a cost-effective
Seekingalpha · 10/16 13:32
The Daily Biotech Pulse: Patent Award For Theratechnologies, Enzo Biochem's Q4, Codiak Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 13)
Benzinga · 10/14 11:53
The Daily Biotech Pulse: J&J Pauses Coronavirus Vaccine Studies, Voyager's Huntington's Disease Study Placed On Hold, Altimmune Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 12)
Benzinga · 10/13 12:20
Immunovant started at buy with $46 stock price target at Stifel Nicolaus
IMVT | Complete Immunovant Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
marketwatch.com · 10/08 12:24
Alexion Pharmaceuticals Expects To Hike Its 2020 Sales Guidance; ALXN Stock Rises
Investor's Business Daily · 10/06 14:35
The First SPAC ETF - SPAK
1-click SPAC portfolio. Should you invest in SPACs? Should you invest in SPAK?
Seekingalpha · 10/02 16:02
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMVT. Analyze the recent business situations of Immunovant Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMVT stock price target is 47.60 with a high estimate of 63.00 and a low estimate of 39.00.
EPS
Institutional Holdings
Institutions: 92
Institutional Holdings: 28.15M
% Owned: 32.32%
Shares Outstanding: 87.08M
TypeInstitutionsShares
Increased
29
7.59M
New
45
9.05M
Decreased
11
1.48M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.60%
Pharmaceuticals & Medical Research
-1.55%
Key Executives
Chairman/Director
Frank Torti
Chief Executive Officer/Director
Peter Salzmann
Chief Financial Officer
Pamela Connealy
Chief Technology Officer
Julia Butchko
Chief Scientific Officer
Michael Elliott
General Counsel
W. Bradford Middlekauff
Director
Eric Venker
Independent Director
Andrew Fromkin
Independent Director
Douglas Hughes
Independent Director
George Migausky
Independent Director
Atul Pande
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About IMVT
Immunovant, Inc., formerly Health Sciences Acquisitions Corp, is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients with autoimmune diseases. It is developing IMVT-1401, a human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. IMVT-1401 is being developed to target the neonatal Fc receptor (FcRn).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Immunovant Inc stock information, including NASDAQ:IMVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMVT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMVT stock methods without spending real money on the virtual paper trading platform.